Chemotherapeutic compounds targeting the DNA double-strand break repair pathways: The good, the bad, and the promising

Frontiers in Oncology

Volumn 4 APR, Issue , 2014, Pages

  Jekimovs, Christian ^a   Bolderson, Emma ^a   Suraweera, Amila ^a   Adams, Mark ^a   O'Byrne, Kenneth J ^a   Richard, Derek J ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Cancer; Chemotherapeutic compounds; DNA damage repair; DNA damage response; DNA double strand break; Radioprotective; Radiosensitize

Indexed keywords

5 (3 FLUOROPHENYL) N (3 PIPERIDINYL) 3 UREIDO 2 THIOPHENECARBOXAMIDE; 7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; CAMPTOTHECIN; CEP 8983; CISPLATIN; CP 466722; DOXORUBICIN; ETOPOSIDE; GDC 0425; GDC 0575; GEMCITABINE; IRINOTECAN; KU 59403; KU 60019; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NIRAPARIB; OLAPARIB; PEMETREXED; PF 00477736; PROTEIN P53; RABUSERTIB; RAD51 PROTEIN; RESVERATROL; SAR 020106; SCH 900776; TELOMELYSIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 844;

APOPTOSIS; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; CHINESE MEDICINE; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DOUBLE STRANDED DNA BREAK; DRUG DOSE ESCALATION; EXCISION REPAIR; GENE MUTATION; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PHOSPHORYLATION; PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH;

EID: 84900992987     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00086     Document Type: Review

References (196)

1. Collis SJ, Boulton SJ. Emerging links between the biological clock and the DNA damage response. Chromosoma (2007) 116:331-9. doi: 10.1007/s00412-007-0108-6.
2. Yang DQ, Kastan MB. Participation of ATM in insulin signalling through phosphorylation of eIF-4E-binding protein 1. Nat Cell Biol (2000) 2:893-8. doi:10.1038/35046542.
3. Sprung CN, Bryan TM, Reddel RR, Murnane JP. Normal telomere maintenance in immortal ataxia telangiectasia cell lines. Mutat Res (1997) 379:177-84. doi:10.1016/S0027-5107(97)00119-X.
4. Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science (1995) 268:1749-53. doi:10.1126/science.7792600.
5. Boder E. Ataxia-telangiectasia: an overview. Kroc Found Ser (1985) 19:1-63.
6. Weemaes CM, Hustinx TW, Scheres JM, van Munster PJ, Bakkeren JA, Taalman RD. A new chromosomal instability disorder: the Nijmegen breakage syndrome. Acta Paediatr Scand (1981) 70:557-64. doi:10.1111/j.1651-2227.1981.tb05740.x.
7. Hartwell L, Weinert T, Kadyk L, Garvik B. Cell cycle checkpoints, genomic integrity, and cancer. Cold Spring Harb Symp Quant Biol (1994) 59:259-63. doi:10.1101/SQB.1994.059.01.030.
8. Krishnan B, Morgan GJ. Non-Hodgkin lymphoma secondary to cancer chemotherapy. Cancer Epidemiol Biomarkers Prev (2007) 16:377-80. doi:10.1158/1055-9965.EPI-06-1069.
9. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 434:917-21. doi:10.1038/nature03445.
10. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature (2005) 434:913-7. doi:10.1038/nature03443.
11. Vilenchik MM, Knudson AG. Endogenous DNA double-strand breaks: production, fidelity of repair, and induction of cancer. Proc Natl Acad Sci U S A (2003) 100:12871-6. doi:10.1073/pnas.2135498100.
12. Shrivastav M, De Haro LP, Nickoloff JA. Regulation of DNA double- strand break repair pathway choice. Cell Res (2008) 18:134-47. doi:10.1038/cr.2007.111.
13. Saleh-Gohari N, Bryant HE, Schultz N, Parker KM, Cassel TN, Helleday T. Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks. Mol Cell Biol (2005) 25:7158-69. doi:10.1128/MCB.25.16.7158-7169.2005.
14. Richard DJ, Bolderson E, Cubeddu L, Wadsworth RI, Savage K, Sharma GG, et al. Single-stranded DNA-binding protein hSSB1 is critical for genomic stability. Nature (2008) 453:677-81. doi:10.1038/nature06883.
15. Richard DJ, Cubeddu L, Urquhart AJ, Bain A, Bolderson E, Menon D, et al. hSSB1 interacts directly with the MRN complex stimulating its recruitment to DNA double-strand breaks and its endo-nuclease activity. Nucleic Acids Res (2011) 39:3643-51. doi:10.1093/nar/gkq1340.
16. Richard DJ, Savage K, Bolderson E, Cubeddu L, So S, Ghita M, et al. hSSB1 rapidly binds at the sites of DNA double-strand breaks and is required for the efficient recruitment of the MRN complex. Nucleic Acids Res (2011) 39:1692-702. doi:10.1093/nar/gkq1098.
17. Limbo O, Chahwan C, Yamada Y, De Bruin RA, Wittenberg C, Russell P. Ctp1 is a cell-cycle-regulated protein that functions with Mre11 complex to control double-strand break repair by homologous recombination. Mol Cell (2007) 28:134-46. doi:10.1016/j.molcel.2007.09.009.
18. Takeda S, Nakamura K, Taniguchi Y, Paull TT. Ctp1/CtIP and the MRN complex collaborate in the initial steps of homologous recombination. Mol Cell (2007) 28:351-2. doi:10.1016/j.molcel.2007.10.016.
19. Tomimatsu N, Mukherjee B, Deland K, Kurimasa A, Bolderson E, Khanna KK, et al. Exo1 plays a major role in DNA end resection in humans and influences double-strand break repair and damage signaling decisions. DNA Repair (2012) 11:441-8. doi:10.1016/j.dnarep.2012.01.006.
20. Garcia V, Phelps SE, Gray S, Neale MJ. Bidirectional resection of DNA double-strand breaks by Mre11 and Exo1. Nature (2011) 479:241-4. doi:10.1038/nature10515.
21. Bolderson E, Tomimatsu N, Richard DJ, Boucher D, Kumar R, Pandita TK, et al. Phosphorylation of Exo1 modulates homologous recombination repair of DNA double-strand breaks. Nucleic Acids Res (2010) 38:1821-31. doi:10.1093/nar/gkp1164.
22. Chen L, Nievera CJ, Lee AY, Wu X. Cell cycle-dependent complex formation of BRCA1.CtIP.MRN is important for DNA double-strand break repair. J Biol Chem (2008) 283:7713-20. doi:10.1074/jbc.M710245200.
23. Yuan SS, Lee SY, Chen G, Song M, Tomlinson GE, Lee EY. BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. Cancer Res (1999) 59:3547-51.
24. Helleday T, Lo J, van Gent DC, Engelward BP. DNA double-strand break repair: from mechanistic understanding to cancer treatment. DNA Repair (Amst) (2007) 6:923-35. doi:10.1016/j.dnarep.2007.02.006.
25. Lee JH, Paull TT. ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science (2005) 308:551-4. doi:10.1126/science.1108297.
26. Matsuura S, Tauchi H, Nakamura A, Kondo N, Sakamoto S, Endo S, et al. Positional cloning of the gene for Nijmegen breakage syndrome. Nat Genet (1998) 19:179-81. doi:10.1038/549.
27. Stewart GS, Maser RS, Stankovic T, Bressan DA, Kaplan MI, Jaspers NG, et al. The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder. Cell (1999) 99:577-87. doi:10.1016/S0092-8674(00)81547-0.
28. Waltes R, Kalb R, Gatei M, Kijas AW, Stumm M, Sobeck A, et al. Human RAD50 deficiency in a Nijmegen breakage syndrome-like disorder. Am J Hum Genet (2009) 84:605-16. doi:10.1016/j.ajhg.2009.04.010.
29. Xiao Y, Weaver DT. Conditional gene targeted deletion by CRE recombinase demonstrates the requirement for the double-strand break repair Mre11 protein in murine embryonic stem cells. Nucleic Acids Res (1997) 25:2985-91. doi:10.1093/nar/25.15.2985.
30. Zhu J, Petersen S, Tessarollo L, Nussenzweig A. Targeted disruption of the Nijmegen breakage syndrome gene NBS1 leads to early embryonic lethality in mice. Curr Biol (2001) 11:105-9. doi:10.1016/S0960-9822(01)00019-7.
31. Luo G, Yao MS, Bender CF, Mills M, Bladl AR, Bradley A, et al. Disruption of mRad50 causes embryonic stem cell lethality, abnormal embryonic development, and sensitivity to ionizing radiation. Proc Natl Acad Sci U S A (1999) 96:7376-81. doi:10.1073/pnas.96.13.7376.
32. Dupre A, Boyer-Chatenet L, Sattler RM, Modi AP, Lee JH, Nicolette ML, et al. A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex. Nat Chem Biol (2008) 4:119-25. doi:10.1038/nchembio.63.
33. Rass E, Grabarz A, Plo I, Gautier J, Bertrand P, Lopez BS. Role of Mre11 in chromosomal nonhomologous end joining in mammalian cells. Nat Struct Mol Biol (2009) 16:819-24. doi:10.1038/nsmb.1641.
34. Tran HM, Shi G, Li G, Carney JP, O'Malley B, Li D. Mutant Nbs1 enhances cisplatin-induced DNA damage and cytotoxicity in head and neck cancer. Otolaryngol Head Neck Surg (2004) 131:477-84. doi:10.1016/j.otohns.2004.04.019.
35. Abuzeid WM, Jiang X, Shi G, Wang H, Paulson D, Araki K, et al. Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy. J Clin Invest (2009) 119:1974-85. doi:10.1172/JCI33816.
36. Kuroda S, Fujiwara T, Shirakawa Y, Yamasaki Y, Yano S, Uno F, et al. Telomerase-dependent oncolytic adenovirus sensitizes human cancer cells to ionizing radiation via inhibition of DNA repair machinery. Cancer Res (2010) 70:9339-48. doi:10.1158/0008-5472.CAN-10-2333.
37. Stracker TH, Carson CT, Weitzman MD. Adenovirus oncoproteins inactivate the Mre11-Rad50-NBS1 DNA repair complex. Nature (2002) 418:348-52. doi:10.1038/nature00863.
38. Kuroda S, Urata Y, Fujiwara T. Ataxia-telangiectasia mutated and the Mre11-Rad50-NBS1 complex: promising targets for radiosensitization. Acta Med Okayama (2012) 66:83-92.
39. Nemunaitis J, Tong AW, Nemunaitis M, Senzer N, Phadke AP, Bedell C, et al. A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Ther (2010) 18:429-34. doi:10.1038/mt.2009.262.
40. Ragione FD, Cucciolla V, Borriello A, Pietra VD, Racioppi L, Soldati G, et al. Resveratrol arrests the cell division cycle at S/G2 phase transition. Biochem Biophys Res Commun (1998) 250:53-8. doi:10.1006/bbrc.1998.9263.
41. Mizutani K, Ikeda K, Kawai Y, Yamori Y. Resveratrol stimulates the proliferation and differentiation of osteoblastic MC3T3-E1 cells. Biochem Biophys Res Commun (1998) 253:859-63. doi:10.1006/bbrc.1998.9870.
42. Clement MV, Hirpara JL, Chawdhury SH, Pervaiz S. Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood (1998) 92:996-1002.
43. Leon-Galicia I, Diaz-Chavez J, Garcia-Villa E, Uribe-Figueroa L, Hidalgo-Miranda A, Herrera LA, et al. Resveratrol induces downregulation of DNA repair genes in MCF-7 human breast cancer cells. Eur J Cancer Prev (2013) 22:11-20. doi:10.1097/CEJ.0b013e328353edcb.
44. Carter LG, D'Orazio JA, Pearson KJ. Resveratrol and cancer: a focus on in vivo evidence. Endocr Relat Cancer (2014). doi:10.1530/ERC-13-0171.
45. Uziel T, Lerenthal Y, Moyal L, Andegeko Y, Mittelman L, Shiloh Y. Requirement of the MRN complex for ATM activation by DNA damage. EMBO J (2003) 22:5612-21. doi:10.1093/emboj/cdg541.
46. Shiloh Y, Ziv Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol (2013) 14:197-210. doi:10.1038/nrm3546.
47. Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER III, Hurov KE, Luo J, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science (2007) 316:1160-6. doi:10.1126/science.1140321.
48. Yang DQ, Halaby MJ, Li Y, Hibma JC, Burn P. Cytoplasmic ATM protein kinase: an emerging therapeutic target for diabetes, cancer and neuronal degeneration. Drug Discov Today (2011) 16:332-8. doi:10.1016/j.drudis.2011.02.001.
49. Eaton JS, Lin ZP, Sartorelli AC, Bonawitz ND, Shadel GS. Ataxia-telangiectasia mutated kinase regulates ribonucleotide reductase and mitochondrial homeostasis. J Clin Invest (2007) 117:2723-34. doi:10.1172/JCI31604.
50. Yao Z, Jones AW, Fassone E, Sweeney MG, Lebiedzinska M, Suski JM, et al. Pgc-1 beta mediates adaptive chemoresistance associated with mitochondrial DNA mutations. Oncogene (2013) 32:2592-600. doi:10.1038/onc.2012.259.
51. Blasina A, Price BD, Turenne GA, McGowan CH. Caffeine inhibits the checkpoint kinase ATM. Curr Biol (1999) 9:1135-8. doi:10.1016/S0960-9822(99)80486-2.
52. Sarkaria JN, Tibbetts RS, Busby EC, Kennedy AP, Hill DE, Abraham RT. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res (1998) 58:4375-82.
53. Matter WF, Brown RF, Vlahos CJ. The inhibition of phosphatidylinositol 3-kinase by quercetin and analogs. Biochem Biophys Res Commun (1992) 186:624-31. doi:10.1016/0006-291X(92)90792-J.
54. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem (1994) 269:5241-8.
55. Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NM, Orr AI, et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res (2004) 64:9152-9. doi:10.1158/0008-5472.CAN-04-2727.
56. Rosenzweig KE, Youmell MB, Palayoor ST, Price BD. Radiosensitization of human tumor cells by the phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay. Clin Cancer Res (1997) 3:1149-56.
57. Welling A, Hofmann F, Wegener JW. Inhibition of L-type Cav1.2 Ca2+ channels by 2,(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) and 2-[1-(3-dimethyl-aminopropyl)-5-methoxy indol-3-yl]-3-(1H-indol-3-yl) maleimide (Go6983). Mol Pharmacol (2005) 67:541-4. doi:10.1124/mol.104.006049.
58. Pasapera Limon AM, Herrera-Munoz J, Gutierrez-Sagal R, Ulloa-Aguirre A. The phosphatidylinositol 3-kinase inhibitor LY294002 binds the estrogen receptor and inhibits 17 beta-estradiol-induced transcriptional activity of an estrogen sensitive reporter gene. Mol Cell Endocrinol (2003) 200:199-202. doi:10.1016/S0303-7207(02)00421-5.
59. Golding SE, Rosenberg E, Valerie N, Hussaini I, Frigerio M, Cockcroft XF, et al. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol Cancer Ther (2009) 8:2894-902. doi:10.1158/1535-7163.MCT-09-0519.
60. Golding SE, Rosenberg E, Adams BR, Wignarajah S, Beckta JM, O'Connor MJ, et al. Dynamic inhibition of ATM kinase provides a strategy for glioblastoma multiforme radiosensitization and growth control. Cell Cycle (2012) 11:1167-73. doi:10.4161/cc.11.6.19576.
61. Rainey MD, Charlton ME, Stanton RV, Kastan MB. Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. Cancer Res (2008) 68:7466-74. doi:10.1158/0008-5472.CAN-08-0763.
62. Batey MA, Zhao Y, Kyle S, Richardson C, Slade A, Martin NM, et al. Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer. Mol Cancer Ther (2013) 12:959-67. doi:10.1158/1535-7163.MCT-12-0707.
63. Won J, Kim M, Kim N, Ahn JH, Lee WG, Kim SS, et al. Retraction: small molecule-based reversible reprogramming of cellular lifespan. Nat Chem Biol (2008) 4:431. doi:10.1038/nchembio0708-431.
64. Choi S, Toledo LI, Fernandez-Capetillo O, Bakkenist CJ. CGK733 does not inhibit ATM or ATR kinase activity in H460 human lung cancer cells. DNA Repair (Amst) (2011) 10:1000-1. doi:10.1016/j.dnarep.2011.07.013.
65. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell (2003) 3:421-9. doi:10.1016/S1535-6108(03)00110-7.
66. Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H, et al. Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to CDK regulation through Cdc25. Science (1997) 277:1497-501. doi:10.1126/science.277.5331.1497.
67. Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene (2001) 20:1803-15. doi:10.1038/sj.onc.1204252.
68. Sorensen CS, Hansen LT, Dziegielewski J, Syljuasen RG, Lundin C, Bartek J, et al. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol (2005) 7:195-201. doi:10.1038/ncb1212.
69. Takai H, Tominaga K, Motoyama N, Minamishima YA, Nagahama H, Tsukiyama T, et al. Aberrant cell cycle checkpoint function and early embryonic death in Chk1(-/-) mice. Genes Dev (2000) 14:1439-47.
70. Graves PR, Yu L, Schwarz JK, Gales J, Sausville EA, O'Connor PM, et al. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem (2000) 275:5600-5. doi:10.1074/jbc.275.8.5600.
71. Busby EC, Leistritz DF, Abraham RT, Karnitz LM, Sarkaria JN. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res (2000) 60:2108-12.
72. Matthews DJ, Yakes FM, Chen J, Tadano M, Bornheim L, Clary DO, et al. Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Cell Cycle (2007) 6:104-10. doi:10.4161/cc.6.1.3699.
73. Riesterer O, Matsumoto F, Wang L, Pickett J, Molkentine D, Giri U, et al. A novel Chk inhibitor, XL-844, increases human cancer cell radiosensitivity through promotion of mitotic catastrophe. Invest New Drugs (2011) 29:514-22. doi:10.1007/s10637-009-9361-2.
74. Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther (2008) 7:2955-66. doi:10.1158/1535-7163.MCT-08-0492.
75. Ma Z, Yao G, Zhou B, Fan Y, Gao S, Feng X. The Chk1 inhibitor AZD7762 sensitises p53 mutant breast cancer cells to radiation in vitro and in vivo. Mol Med Rep (2012) 6:897-903. doi:10.3892/mmr.2012.999.
76. Seto T, Esaki T, Hirai F, Arita S, Nosaki K, Makiyama A, et al. Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours. Cancer Chemother Pharmacol (2013) 72:619-27. doi:10.1007/s00280-013-2234-6.
77. Blasina A, Hallin J, Chen E, Arango ME, Kraynov E, Register J, et al. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Mol Cancer Ther (2008) 7:2394-404. doi:10.1158/1535-7163.MCT-07-2391.
78. Zhang C, Yan Z, Painter CL, Zhang Q, Chen E, Arango ME, et al. PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts. Clin Cancer Res (2009) 15:4630-40. doi:10.1158/1078-0432.CCR-08-3272.
79. Guzi TJ, Paruch K, Dwyer MP, Labroli M, Shanahan F, Davis N, et al. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther (2011) 10:591-602. doi:10.1158/1535-7163.MCT-10-0928.
80. Schenk EL, Koh BD, Flatten KS, Peterson KL, Parry D, Hess AD, et al. Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro. Clin Cancer Res (2012) 18:5364-73. doi:10.1158/1078-0432.CCR-12-0961.
81. Montano R, Chung I, Garner KM, Parry D, Eastman A. Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites. Mol Cancer Ther (2012) 11:427-38. doi:10.1158/1535-7163.MCT-11-0406.
82. Montano R, Thompson R, Chung I, Hou H, Khan N, Eastman A. Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo. BMC Cancer (2013) 13:604. doi:10.1186/1471-2407-13-604.
83. Karp JE, Thomas BM, Greer JM, Sorge C, Gore SD, Pratz KW, et al. Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor SCH 900776 in refractory acute leukemias. Clin Cancer Res (2012) 18:6723-31. doi:10.1158/1078-0432.CCR-12-2442.
84. King C, Diaz H, Barnard D, Barda D, Clawson D, Blosser W, et al. Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs (2013) 32(2):213-26. doi:10.1007/s10637-013-0036-7.
85. Weiss GJ, Donehower RC, Iyengar T, Ramanathan RK, Lewandowski K, Westin E, et al. Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer. Invest New Drugs (2013) 31:136-44. doi:10.1007/s10637-012-9815-9.
86. Borst GR, McLaughlin M, Kyula JN, Neijenhuis S, Khan A, Good J, et al. Targeted radiosensitization by the Chk1 inhibitor SAR-020106. Int J Radiat Oncol Biol Phys (2013) 85:1110-8. doi:10.1016/j.ijrobp.2012.08.006.
87. Walton MI, Eve PD, Hayes A, Valenti M, De Haven Brandon A, Box G, et al. The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106. Mol Cancer Ther (2010) 9:89-100. doi:10.1158/1535-7163.MCT-09-0938.
88. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res (1994) 54:4855-78.
89. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer (2004) 4:793-805. doi:10.1038/nrc1455.
90. Wolf JK, Bodurka DC, Gano JB, Deavers M, Ramondetta L, Ramirez PT, et al. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer. Gynecol Oncol (2004) 94:442-8. doi:10.1016/j.ygyno.2004.05.041.
91. Zhang S, Li Y, Li L, Zhang Y, Gao N, Zhang Z, et al. Phase I study of repeated intraepithelial delivery of adenoviral p53 in patients with dysplastic oral leukoplakia. J Oral Maxillofac Surg (2009) 67:1074-82. doi:10.1016/j.joms.2008.06.079.
92. Buller RE, Runnebaum IB, Karlan BY, Horowitz JA, Shahin M, Buekers T, et al. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther (2002) 9:553-66. doi:10.1038/sj.cgt.7700472.
93. van Beusechem VW, van den Doel PB, Grill J, Pinedo HM, Gerritsen WR. Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Res (2002) 62:6165-71.
94. Wang X, Su C, Cao H, Li K, Chen J, Jiang L, et al. A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy on common human solid cancers. Mol Cancer Ther (2008) 7:1598-603. doi:10.1158/1535-7163.MCT-07-2429.
95. Yamasaki Y, Tazawa H, Hashimoto Y, Kojima T, Kuroda S, Yano S, et al. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression. Eur J Cancer (2012) 48:2282-91. doi:10.1016/j.ejca.2011.12.020.
96. Takimoto R, Wang W, Dicker DT, Rastinejad F, Lyssikatos J, El-Deiry WS. The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther (2002) 1:47-55. doi:10.4161/cbt.1.1.41.
97. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med (2002) 8:282-8. doi:10.1038/nm0302-282.
98. Friedler A, Hansson LO, Veprintsev DB, Freund SM, Rippin TM, Nikolova PV, et al. A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci U S A (2002) 99:937-42. doi:10.1073/pnas.241629998.
99. Selivanova G, Ryabchenko L, Jansson E, Iotsova V, Wiman KG. Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain. Mol Cell Biol (1999) 19:3395-402.
100. Demma M, Maxwell E, Ramos R, Liang L, Li C, Hesk D, et al. SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53. J Biol Chem (2010) 285:10198-212. doi:10.1074/jbc.M109.083469.
101. Givalos N, Gakiopoulou H, Skliri M, Bousboukea K, Konstantinidou AE, Korkolopoulou P, et al. Replication protein A is an independent prognostic indicator with potential therapeutic implications in colon cancer. Mod Pathol (2007) 20:159-66. doi:10.1038/modpathol.3800719.
102. Dahai Y, Sanyuan S, Hong L, Di Z, Chong Z. A relationship between replication protein A and occurrence and prognosis of esophageal carcinoma. Cell Biochem Biophys (2013) 67:175-80. doi:10.1007/s12013-013-9530-y.
103. Tomkiel JE, Alansari H, Tang N, Virgin JB, Yang X, Vandevord P, et al. Autoimmunity to the M(r) 32,000 subunit of replication protein A in breast cancer. Clin Cancer Res (2002) 8:752-8.
104. Sigurdsson S, Trujillo K, Song B, Stratton S, Sung P. Basis for avid homologous DNA strand exchange by human Rad51 and RPA. J Biol Chem (2001) 276:8798-806. doi:10.1074/jbc.M010011200.
105. Shuck SC, Turchi JJ. Targeted inhibition of replication protein A reveals cytotoxic activity, synergy with chemotherapeutic DNA-damaging agents, and insight into cellular function. Cancer Res (2010) 70:3189-98. doi:10.1158/0008-5472.CAN-09-3422.
106. Andrews BJ, Turchi JJ. Development of a high-throughput screen for inhibitors of replication protein A and its role in nucleotide excision repair. Mol Cancer Ther (2004) 3:385-91.
107. Neher TM, Bodenmiller D, Fitch RW, Jalal SI, Turchi JJ. Novel irreversible small molecule inhibitors of replication protein A display single-agent activity and synergize with cisplatin. Mol Cancer Ther (2011) 10:1796-806. doi:10.1158/1535-7163.MCT-11-0303.
108. Oakley GG, Tillison K, Opiyo SA, Glanzer JG, Horn JM, Patrick SM. Physical interaction between replication protein A (RPA) and MRN: involvement of RPA2 phosphorylation and the N-terminus of RPA1. Biochemistry (2009) 48:7473-81. doi:10.1021/bi900694p.
109. Stauffer ME, Chazin WJ. Physical interaction between replication protein A and Rad51 promotes exchange on single-stranded DNA. J Biol Chem (2004) 279:25638-45. doi:10.1074/jbc.M400029200.
110. Wong JM, Ionescu D, Ingles CJ. Interaction between BRCA2 and replication protein A is compromised by a cancer-predisposing mutation in BRCA2. Oncogene (2003) 22:28-33. doi:10.1038/sj.onc.1206071.
111. Tsuzuki T, Fujii Y, Sakumi K, Tominaga Y, Nakao K, Sekiguchi M, et al. Targeted disruption of the Rad51 gene leads to lethality in embryonic mice. Proc Natl Acad Sci U S A (1996) 93:6236-40. doi:10.1073/pnas.93.13.6236.
112. Baumann P, Benson FE, West SC. Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro. Cell (1996) 87:757-66. doi:10.1016/S0092-8674(00)81394-X.
113. Henning W, Sturzbecher HW. Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance. Toxicology (2003) 193:91-109. doi:10.1016/S0300-483X(03)00291-9.
114. Ohnishi T, Taki T, Hiraga S, Arita N, Morita T. In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene. Biochem Biophys Res Commun (1998) 245:319-24. doi:10.1006/bbrc.1998.8440.
115. Nomme J, Takizawa Y, Martinez SF, Renodon-Corniere A, Fleury F, Weigel P, et al. Inhibition of filament formation of human Rad51 protein by a small peptide derived from the BRC-motif of the BRCA2 protein. Genes Cells (2008) 13:471-81. doi:10.1111/j.1365-2443.2008.01180.x.
116. Nomme J, Renodon-Corniere A, Asanomi Y, Sakaguchi K, Stasiak AZ, Stasiak A, et al. Design of potent inhibitors of human RAD51 recombinase based on BRC motifs of BRCA2 protein: modeling and experimental validation of a chimera peptide. J Med Chem (2010) 53:5782-91. doi:10.1021/jm1002974.
117. Huang F, Motlekar NA, Burgwin CM, Napper AD, Diamond SL, Mazin AV. Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening. ACS Chem Biol (2011) 6:628-35. doi:10.1021/cb100428c.
118. Budke B, Logan HL, Kalin JH, Zelivianskaia AS, Cameron McGuire W, Miller LL, et al. RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells. Nucleic Acids Res (2012) 40:7347-57. doi:10.1093/nar/gks353.
119. Budke B, Kalin JH, Pawlowski M, Zelivianskaia AS, Wu M, Kozikowski AP, et al. An optimized RAD51 inhibitor that disrupts homologous recombination without requiring Michael acceptor reactivity. J Med Chem (2013) 56:254-63. doi:10.1021/jm301565b.
120. Zhu J, Zhou L, Wu G, Konig H, Lin X, Li G, et al. A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia. EMBO Mol Med (2013) 5:353-65. doi:10.1002/emmm.201201760.
121. Rosen EM. BRCA1 in the DNA damage response and at telomeres. Front Genet (2013) 4:85. doi:10.3389/fgene.2013.00085.
122. Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer (2012) 12:68-78. doi:10.1038/nrc3181.
123. Hakem R, De La Pompa JL, Mak TW. Developmental studies of BRCA1 and BRCA2 knock-out mice. J Mammary Gland Biol Neoplasia (1998) 3:431-45. doi:10.1023/A:1018792200700.
124. Sharan SK, Morimatsu M, Albrecht U, Lim DS, Regel E, Dinh C, et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature (1997) 386:804-10. doi:10.1038/386804a0.
125. Yu SW, Wang H, Poitras MF, Coombs C, Bowers WJ, Federoff HJ, et al. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science (2002) 297:259-63. doi:10.1126/science.1072221.
126. Kim MY, Mauro S, Gevry N, Lis JT, Kraus WL. NAD+-dependent modulation of chromatin structure and transcription by nucleosome binding properties of PARP-1. Cell (2004) 119:803-14. doi:10.1016/j.cell.2004.11.002.
127. Leppard JB, Dong Z, Mackey ZB, Tomkinson AE. Physical and functional interaction between DNA ligase III alpha and poly(ADP-ribose) polymerase 1 in DNA single-strand break repair. Mol Cell Biol (2003) 23:5919-27. doi:10.1128/MCB.23.16.5919-5927.2003.
128. Saberi A, Hochegger H, Szuts D, Lan L, Yasui A, Sale JE, et al. RAD18 and poly(ADP-ribose) polymerase independently suppress the access of nonhomologous end joining to double-strand breaks and facilitate homologous recombination-mediated repair. Mol Cell Biol (2007) 27:2562-71. doi:10.1128/MCB.01243-06.
129. Clark JB, Ferris GM, Pinder S. Inhibition of nuclear NAD nucleosidase and poly ADP-ribose polymerase activity from rat liver by nicotinamide and 5'-methyl nicotinamide. Biochim Biophys Acta (1971) 238:82-5. doi:10.1016/0005-2787(71)90012-8.
130. Waters R, Ramsay F, Barrett I. 3-Aminobenzamide, an inhibitor of poly ADP-ribose polymerase, decreases the frequency of alkaline labile lesions and increases growth in human fibroblasts exposed to 3-methyl 4-nitroquinoline 1-oxide. Carcinogenesis (1982) 3:1463-7. doi:10.1093/carcin/3.12.1463.
131. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 361:123-34. doi:10.1056/NEJMoa0900212.
132. Hay T, Matthews JR, Pietzka L, Lau A, Cranston A, Nygren AO, et al. Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. Cancer Res (2009) 69:3850-5. doi:10.1158/0008-5472.CAN-08-2388.
133. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet (2010) 376:235-44. doi:10.1016/S0140-6736(10)60892-6.
134. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet (2010) 376:245-51. doi:10.1016/S0140-6736(10)60893-8.
135. Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol (2009) 27:2705-11. doi:10.1200/JCO.2008.19.7681.
136. Kummar S, Chen A, Ji J, Zhang Y, Reid JM, Ames M, et al. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res (2011) 71:5626-34. doi:10.1158/0008-5472.CAN-11-1227.
137. O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med (2011) 364:205-14. doi:10.1056/NEJMoa1011418.
138. Liu X, Shi Y, Maag DX, Palma JP, Patterson MJ, Ellis PA, et al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res (2012) 18:510-23. doi:10.1158/1078-0432.CCR-11-1973.
139. Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH. Failure of iniparib to inhibit poly(ADP-ribose) polymerase in vitro. Clin Cancer Res (2012) 18:1655-62. doi:10.1158/1078-0432.CCR-11-2890.
140. Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res (2008) 14:7917-23. doi:10.1158/1078-0432.CCR-08-1223.
141. Plummer R, Lorigan P, Steven N, Scott L, Middleton MR, Wilson RH, et al. A phase II study of the potent PARP inhibitor, rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemother Pharmacol (2013) 71:1191-9. doi:10.1007/s00280-013-2113-1.
142. Miknyoczki S, Chang H, Grobelny J, Pritchard S, Worrell C, McGann N, et al. The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. Mol Cancer Ther (2007) 6:2290-302. doi:10.1158/1535-7163.MCT-07-0062.
143. Jones P, Altamura S, Boueres J, Ferrigno F, Fonsi M, Giomini C, et al. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem (2009) 52:7170-85. doi:10.1021/jm901188v.
144. Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol (2013) 14:882-92. doi:10.1016/S1470-2045(13)70240-7.
145. Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res (2013) 19:5003-15. doi:10.1158/1078-0432.CCR-13-1391.
146. Chapman JR, Taylor MR, Boulton SJ. Playing the end game: DNA double-strand break repair pathway choice. Mol Cell (2012) 47:497-510. doi:10.1016/j.molcel.2012.07.029.
147. Mahaney BL, Meek K, Lees-Miller SP. Repair of ionizing radiation-induced DNA double-strand breaks by non-homologous end-joining. Biochem J (2009) 417:639-50. doi:10.1042/BJ20080413.
148. Ader I, Muller C, Bonnet J, Favre G, Cohen-Jonathan E, Salles B, et al. The radioprotective effect of the 24 kDa Fgf-2 isoform in HeLa cells is related to an increased expression and activity of the DNA dependent protein kinase (DNA-PK) catalytic subunit. Oncogene (2002) 21:6471-9. doi:10.1038/sj.onc.1205838.
149. Beskow C, Skikuniene J, Holgersson A, Nilsson B, Lewensohn R, Kanter L, et al. Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86. Br J Cancer (2009) 101:816-21. doi:10.1038/sj.bjc.6605201.
150. Deriano L, Guipaud O, Merle-Beral H, Binet JL, Ricoul M, Potocki-Veronese G, et al. Human chronic lymphocytic leukemia B cells can escape DNA damage-induced apoptosis through the nonhomologous end-joining DNA repair pathway. Blood (2005) 105:4776-83. doi:10.1182/blood-2004-07-2888.
151. Miquel C, Jacob S, Grandjouan S, Aime A, Viguier J, Sabourin JC, et al. Frequent alteration of DNA damage signalling and repair pathways in human colorectal cancers with microsatellite instability. Oncogene (2007) 26:5919-26. doi:10.1038/sj.onc.1210419.
152. Davidson D, Amrein L, Panasci L, Aloyz R. Small molecules, inhibitors of DNA-PK, targeting DNA repair, and beyond. Front Pharmacol (2013) 4:5. doi:10.3389/fphar.2013.00005.
153. Allen C, Halbrook J, Nickoloff JA. Interactive competition between homologous recombination and non-homologous end joining. Mol Cancer Res (2003) 1:913-20.
154. Collis SJ, Deweese TL, Jeggo PA, Parker AR. The life and death of DNA-PK. Oncogene (2005) 24:949-61. doi:10.1038/sj.onc.1208332.
155. Fuhrman CB, Kilgore J, Lacoursiere YD, Lee CM, Milash BA, Soisson AP, et al. Radiosensitization of cervical cancer cells via double-strand DNA break repair inhibition. Gynecol Oncol (2008) 110:93-8. doi:10.1016/j.ygyno.2007.08.073.
156. Peddi P, Loftin CW, Dickey JS, Hair JM, Burns KJ, Aziz K, et al. DNA-PKcs deficiency leads to persistence of oxidatively induced clustered DNA lesions in human tumor cells. Free Radic Biol Med (2010) 48:1435-43. doi:10.1016/j.freeradbiomed.2010.02.033.
157. Willmore E, De Caux S, Sunter NJ, Tilby MJ, Jackson GH, Austin CA, et al. A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. Blood (2004) 103:4659-65. doi:10.1182/blood-2003-07-2527.
158. Hollick JJ, Golding BT, Hardcastle IR, Martin N, Richardson C, Rigoreau LJ, et al. 2,6-Disubstituted pyran-4-one and thiopyran-4-one inhibitors of DNA-dependent protein kinase (DNA-PK). Bioorg Med Chem Lett (2003) 13:3083-6. doi:10.1016/S0960-894X(03)00652-8.
159. Tavecchio M, Munck JM, Cano C, Newell DR, Curtin NJ. Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination. Cancer Chemother Pharmacol (2012) 69:155-64. doi:10.1007/s00280-011-1662-4.
160. Zhao Y, Thomas HD, Batey MA, Cowell IG, Richardson CJ, Griffin RJ, et al. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res (2006) 66:5354-62. doi:10.1158/0008-5472.CAN-05-4275.
161. Mould E, Berry P, Jamieson D, Hill C, Cano C, Tan N, et al. Identification of dual DNA-PK MDR1 inhibitors for the potentiation of cytotoxic drug activity. Biochem Pharmacol (2014) 88:58-65. doi:10.1016/j.bcp.2014.01.001.
162. Kruszewski M, Wojewodzka M, Iwanenko T, Szumiel I, Okuyama A. Differential inhibitory effect of OK-1035 on DNA repair in L5178Y murine lymphoma sublines with functional or defective repair of double strand breaks. Mutat Res (1998) 409:31-6. doi:10.1016/S0921-8777(98)00040-8.
163. Ismail IH, Martensson S, Moshinsky D, Rice A, Tang C, Howlett A, et al. SU11752 inhibits the DNA-dependent protein kinase and DNA double-strand break repair resulting in ionizing radiation sensitization. Oncogene (2004) 23:873-82. doi:10.1038/sj.onc.1207303.
164. Hisatomi T, Sueoka-Aragane N, Sato A, Tomimasu R, Ide M, Kurimasa A, et al. NK314 potentiates antitumor activity with adult T-cell leukemia-lymphoma cells by inhibition of dual targets on topoisomerase II{alpha} and DNA-dependent protein kinase. Blood (2011) 117:3575-84. doi:10.1182/blood-2010-02-270439.
165. Sibanda BL, Chirgadze DY, Blundell TL. Crystal structure of DNA-PKcs reveals a large open-ring cradle comprised of HEAT repeats. Nature (2010) 463:118-21. doi:10.1038/nature08648.
166. Ihmaid SK, Al-Rawi JM, Bradley CJ, Angove MJ, Robertson MN. Synthesis, DNA-PK inhibition, anti-platelet activity studies of 2-(N-substituted-3-aminopyridine)-substituted-1,3-benzoxazines and DNA-PK and PI3K inhibition, homology modelling studies of 2-morpholino-(7,8-di and 8-substituted)-1,3-benzoxazines. Eur J Med Chem (2012) 57:85-101. doi:10.1016/j.ejmech.2012.08.035.
167. Li YH, Wang X, Pan Y, Lee DH, Chowdhury D, Kimmelman AC. Inhibition of non-homologous end joining repair impairs pancreatic cancer growth and enhances radiation response. PLoS One (2012) 7:e39588. doi:10.1371/journal.pone.0039588.
168. Wei YF, Robins P, Carter K, Caldecott K, Pappin DJ, Yu GL, et al. Molecular cloning and expression of human cDNAs encoding a novel DNA ligase IV and DNA ligase III, an enzyme active in DNA repair and recombination. Mol Cell Biol (1995) 15:3206-16.
169. Critchlow SE, Bowater RP, Jackson SP. Mammalian DNA double-strand break repair protein XRCC4 interacts with DNA ligase IV. Curr Biol (1997) 7:588-98. doi:10.1016/S0960-9822(06)00258-2.
170. Grawunder U, Wilm M, Wu X, Kulesza P, Wilson TE, Mann M, et al. Activity of DNA ligase IV stimulated by complex formation with XRCC4 protein in mammalian cells. Nature (1997) 388:492-5. doi:10.1038/41358.
171. Ahnesorg P, Smith P, Jackson SP. XLF interacts with the XRCC4-DNA ligase IV complex to promote DNA nonhomologous end-joining. Cell (2006) 124:301-13. doi:10.1016/j.cell.2005.12.031.
172. Ellenberger T, Tomkinson AE. Eukaryotic DNA ligases: structural and functional insights. Annu Rev Biochem (2008) 77:313-38. doi:10.1146/annurev.biochem.77.061306.123941.
173. Tomkinson AE, Vijayakumar S, Pascal JM, Ellenberger T. DNA ligases: structure, reaction mechanism, and function. Chem Rev (2006) 106:687-99. doi:10.1021/cr040498d.
174. Chen X, Zhong S, Zhu X, Dziegielewska B, Ellenberger T, Wilson GM, et al. Rational design of human DNA ligase inhibitors that target cellular DNA replication and repair. Cancer Res (2008) 68:3169-77. doi:10.1158/0008-5472.CAN-07-6636.
175. Srivastava M, Nambiar M, Sharma S, Karki SS, Goldsmith G, Hegde M, et al. An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression. Cell (2012) 151:1474-87. doi:10.1016/j.cell.2012.11.054.
176. Mari PO, Florea BI, Persengiev SP, Verkaik NS, Bruggenwirth HT, Modesti M, et al. Dynamic assembly of end-joining complexes requires interaction between Ku70/80 and XRCC4. Proc Natl Acad Sci U S A (2006) 103:18597-602. doi:10.1073/pnas.0609061103.
177. Davis AJ, Chen DJ. DNA double strand break repair via non-homologous end-joining. Transl Cancer Res (2013) 2:130-43.
178. Gao Y, Sun Y, Frank KM, Dikkes P, Fujiwara Y, Seidl KJ, et al. A critical role for DNA end-joining proteins in both lymphogenesis and neurogenesis. Cell (1998) 95:891-902. doi:10.1016/S0092-8674(00)81714-6.
179. Modesti M, Hesse JE, Gellert M. DNA binding of Xrcc4 protein is associated with V(D)J recombination but not with stimulation of DNA ligase IV activity. EMBO J (1999) 18:2008-18. doi:10.1093/emboj/18.7.2008.
180. Sun MF, Chen HY, Tsai FJ, Lui SH, Chen CY, Chen CY. Search for novel remedies to augment radiation resistance of inhabitants of Fukushima and Chernobyl disasters: identifying DNA repair protein XRCC4 inhibitors. J Biomol Struct Dyn (2011) 29:325-37. doi:10.1080/07391102.2011.10507388.
181. McFadden MJ, Lee WK, Brennan JD, Junop MS. Delineation of key XRCC4/ligase IV interfaces for targeted disruption of non-homologous end joining DNA repair. Proteins (2014) 82:187-94. doi:10.1002/prot.24349.
182. Dahm K. Role and regulation of human XRCC4-like factor/cernunnos. J Cell Biochem (2008) 104:1534-40. doi:10.1002/jcb.21726.
183. Iwabuchi K, Bartel PL, Li B, Marraccino R, Fields S. Two cellular proteins that bind to wild-type but not mutant p53. Proc Natl Acad Sci U S A (1994) 91:6098-102. doi:10.1073/pnas.91.13.6098.
184. Adams MM, Carpenter PB. Tying the loose ends together in DNA double strand break repair with 53BP1. Cell Div (2006) 1:19. doi:10.1186/1747-1028-1-19.
185. Panier S, Boulton SJ. Double-strand break repair: 53BP1 comes into focus. Nat Rev Mol Cell Biol (2014) 15:7-18. doi:10.1038/nrm3719.
186. Rappold I, Iwabuchi K, Date T, Chen J. Tumor suppressor p53 binding protein 1 (53BP1) is involved in DNA damage-signaling pathways. J Cell Biol (2001) 153:613-20. doi:10.1083/jcb.153.3.613.
187. McVey M, Lee SE. MMEJ repair of double-strand breaks (director's cut): deleted sequences and alternative endings. Trends Genet (2008) 24:529-38. doi:10.1016/j.tig.2008.08.007.
188. Wang H, Rosidi B, Perrault R, Wang M, Zhang L, Windhofer F, et al. DNA ligase III as a candidate component of backup pathways of nonhomologous end joining. Cancer Res (2005) 65:4020-30. doi:10.1158/0008-5472.CAN-04-3055.
189. Mladenov E, Magin S, Soni A, Iliakis G. DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy. Front Oncol (2013) 3:113. doi:10.3389/fonc.2013.00113.
190. Della-Maria J, Zhou Y, Tsai MS, Kuhnlein J, Carney JP, Paull TT, et al. Human Mre11/human Rad50/Nbs1 and DNA ligase III alpha/XRCC1 protein complexes act together in an alternative nonhomologous end joining pathway. J Biol Chem (2011) 286:33845-53. doi:10.1074/jbc.M111.274159.
191. Zhang Y, Jasin M. An essential role for CtIP in chromosomal translocation formation through an alternative end-joining pathway. Nat Struct Mol Biol (2011) 18:80-4. doi:10.1038/nsmb.1940.
192. Zhong Q, Chen CF, Chen PL, Lee WH. BRCA1 facilitates microhomology-mediated end joining of DNA double strand breaks. J Biol Chem (2002) 277:28641-7. doi:10.1074/jbc.M200748200.
193. Hahnel PS, Enders B, Sasca D, Roos WP, Kaina B, Bullinger L, et al. Targeting components of the alternative NHEJ pathway sensitizes KRAS-mutant leukemic cells to chemotherapy. Blood (2014) 123:2355-66. doi:10.1182/blood-2013-01-477620.
194. Feng Z, Scott SP, Bussen W, Sharma GG, Guo G, Pandita TK, et al. Rad52 inactivation is synthetically lethal with BRCA2 deficiency. Proc Natl Acad Sci U S A (2011) 108:686-91. doi:10.1073/pnas.1010959107.
195. Oike T, Ogiwara H, Tominaga Y, Ito K, Ando O, Tsuta K, et al. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1. Cancer Res (2013) 73:5508-18. doi:10.1158/0008-5472.CAN-12-4593.
196. Knutson SK, Warholic NM, Wigle TJ, Klaus CR, Allain CJ, Raimondi A, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci U S A (2013) 110:7922-7. doi:10.1073/pnas.1303800110.